Inflationary pressures due to global events like the Iran War escalation could increase BioScience Health Innovations' operational costs, affecting profitability. High inflation may also reduce consumer discretionary spending on health products, potentially impacting sales volume.

The 'Higher for Longer' interest rate environment maintained by central banks could increase borrowing costs for BioScience Health Innovations, hindering expansion plans or daily operations if the company relies on debt financing. It may also lead investors to favor more stable assets, reducing capital availability for small-cap, OTC-listed companies.

The ongoing geopolitical tensions and their potential impact on global supply chains could affect the availability and cost of raw materials and ingredients for BioScience Health Innovations' products. This could lead to production delays or increased manufacturing expenses.